Evidence map›Paper›PMID 41790376›Full record

ArticleJournal of clinical immunology2026

The Experience of a Tertiary Reference Center in Central Anatolia with Children Carrying ZAP-70 Variants, Including Two Novel Variants.

Serdar Göktaş, Ozlem Kalaycik Sengul, Şerife Erdem, Hatice Eke Güngör, Royala Babayeva, Sevgi Bilgic-Eltan, Turan Güzel, Koray Dörterler, Meino Rohlfs, Alper Özcan and 14 more

Abstract read
In one paragraph

Article in Journal of clinical immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Serdar GöktaşFaculty of Medicine, Division of Pediatric Immunology and Allergy, Erciyes University, Kayseri, Türkiye.
Ozlem Kalaycik SengulDivision of Pediatric Gastroenterology, Hepatology and Nutrition, Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Türkiye.
Şerife ErdemDepartment of Medical Biology, Faculty of Medicine, Betül-Ziya Eren Genome and Stem Cell Center (GENKOK), Erciyes University, Kayseri, 38030, Türkiye.
Hatice Eke GüngörDepartment of Immunology, School of Medicine, Kırsehir Ahi Evran University, Kırsehir, Türkiye.
Royala BabayevaLeyla Medical Center and Republic Pediatric Center, Baku, Azerbaijan.
Sevgi Bilgic-EltanFaculty of Medicine, Department of Pediatrics, Division of Allergy and Immunology, Marmara University, Istanbul, Türkiye.
Turan GüzelDivision of Pediatric Hematology-Oncology & Pediatric HSCT Unit, Faculty of Medicine, Erciyes University, Kayseri, Türkiye.
Koray DörterlerDepartment of Medical Biology, Faculty of Medicine, Betül-Ziya Eren Genome and Stem Cell Center (GENKOK), Erciyes University, Kayseri, 38030, Türkiye.
Meino RohlfsDepartment of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.
Alper ÖzcanDivision of Pediatric Hematology-Oncology & Pediatric HSCT Unit, Faculty of Medicine, Erciyes University, Kayseri, Türkiye.
Ebru YilmazDivision of Pediatric Hematology-Oncology & Pediatric HSCT Unit, Faculty of Medicine, Erciyes University, Kayseri, Türkiye.
Musa KarakukcuDivision of Pediatric Hematology-Oncology & Pediatric HSCT Unit, Faculty of Medicine, Erciyes University, Kayseri, Türkiye.
Haluk Himmet AkarDivision of Pediatric Immunology and Allergy, Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Türkiye.
Elif Karakoc-AydinerFaculty of Medicine, Department of Pediatrics, Division of Allergy and Immunology, Marmara University, Istanbul, Türkiye.
Ahmet ÖzenFaculty of Medicine, Department of Pediatrics, Division of Allergy and Immunology, Marmara University, Istanbul, Türkiye.
Muhsin ElmasDepartment of Medical Genetics, Medipol Mega University Hospital, Istanbul, Turkey.
Türkan PatiroğluFaculty of Medicine, Division of Pediatric Immunology and Allergy, Erciyes University, Kayseri, Türkiye.
Muhammet E DoğanClinic of Medical Genetics, Kayseri City Hospital, Kayseri, Türkiye.
Hasan BaşDepartment of Medical Genetics, Intergen Genetics and Rare Diseases Diagnosis Research & Application Center, Ankara, Türkiye.
Naomi TaylorInstitut de Genetique Moleculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France.
Safa BarisFaculty of Medicine, Department of Pediatrics, Division of Allergy and Immunology, Marmara University, Istanbul, Türkiye.
Christoph KleinDepartment of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.
Ahmet EkenDepartment of Medical Biology, Faculty of Medicine, Betül-Ziya Eren Genome and Stem Cell Center (GENKOK), Erciyes University, Kayseri, 38030, Türkiye. ahmet.eken@gmail.com.ORCID http://orcid.org/0000-0002-5816-0686
Ekrem ÜnalDivision of Pediatric Hematology-Oncology & Pediatric HSCT Unit, Faculty of Medicine, Erciyes University, Kayseri, Türkiye. drekremunal@yahoo.com.tr.ORCID http://orcid.org/0000-0002-2691-4826

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeZeta-chain-associated protein kinase 70 (ZAP-70) deficiency, a rare form of combined immunodeficiency (CID), is caused by homozygous or compound heterozygous variants in the ZAP70 gene. ZAP-70, a tyrosine kinase, plays a key role in T-cell receptor (TCR) signaling, which is critical for T cell activation. ZAP-70 deficiency manifests clinically in a variety of ways, including recurring respiratory infections and cutaneous manifestations.

methodsThis study describes the clinical, genetic, and immunological characteristics of four Turkish, two Syrian, and one Azerbaijani patient with ZAP-70 deficiency, including two novel variants.

resultsAmong seven patients diagnosed with ZAP-70 deficiency, two previously unreported ZAP70 variants were identified. Functional analyses performed in four patients—including three with novel variants—demonstrated impaired TCR-induced proliferation, reduced Interleukin 2 (IL-2) production, and markedly diminished CD8⁺ T cell numbers, supporting the pathogenicity of these variants. Clinical phenotypes were heterogeneous, ranging from severe early-onset infections and cytopenias to autoimmune manifestations and atopy. Notably, even siblings carrying the same variant exhibited divergent immunological profiles and disease severity, highlighting the influence of potential genetic or environmental modifiers. Hematopoietic stem cell transplantation (HSCT) was curative in four patients, while one patient died before transplant.

conclusionThis report expands the genetic and phenotypic spectrum of ZAP-70 deficiency by describing two novel variants and emphasizing the value of functional analysis in variant classification and patient management.

Indexed as

Genetic VariationImmunologic Deficiency SyndromesMutationZAP-70 Protein-Tyrosine KinaseChildChild, PreschoolFemaleGenetic Association StudiesGenetic Predisposition to DiseaseHumansInfantLymphocyte ActivationMalePhenotypeReceptors, Antigen, T-CellSevere Combined ImmunodeficiencyReceptors, Antigen, T-CellZAP70 protein, humanZAP-70 Protein-Tyrosine KinaseCombined immunodeficiencyNovel variantsZAP-70 deficiency

Identifiers

PMID41790376
PMCPMC13004735

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.